W

ASHINGTON — Republicans on the House Energy and Commerce Committee are gearing up to overhaul a controversial Medicare drug discount program as soon as this quarter, a key Republican tells STAT. That’s a win for drug makers who have long pushed to narrow the scope of the so-called 340B drug discount program.

At the same time, however, the committee will also examine whether to restore a recent $1.6 billion cut to the program, which came under a Trump administration rule that took effect Jan. 1, according to committee Chairman Greg Walden of Oregon. Hospital groups have called the cut “devastating” and have lobbied Congress to reverse it.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.